200 related articles for article (PubMed ID: 28363321)
21. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis.
Bahji A; Cheng B; Gray S; Stuart H
Acta Psychiatr Scand; 2019 Oct; 140(4):313-339. PubMed ID: 31419306
[TBL] [Abstract][Full Text] [Related]
22. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
23. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses.
Hadland SE; Rivera-Aguirre A; Marshall BDL; Cerdá M
JAMA Netw Open; 2019 Jan; 2(1):e186007. PubMed ID: 30657529
[TBL] [Abstract][Full Text] [Related]
24. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
[TBL] [Abstract][Full Text] [Related]
25. The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose.
Karmali RN; Ray GT; Rubinstein AL; Sterling SA; Weisner CM; Campbell CI
Drug Alcohol Depend; 2020 Apr; 209():107923. PubMed ID: 32126455
[TBL] [Abstract][Full Text] [Related]
26. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US.
Ballreich J; Mansour O; Hu E; Chingcuanco F; Pollack HA; Dowdy DW; Alexander GC
JAMA Netw Open; 2020 Nov; 3(11):e2023677. PubMed ID: 33146732
[TBL] [Abstract][Full Text] [Related]
27. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
[TBL] [Abstract][Full Text] [Related]
28. Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study.
Wei YJ; Chen C; Fillingim R; Schmidt SO; Winterstein AG
PLoS Med; 2019 Nov; 16(11):e1002941. PubMed ID: 31689302
[TBL] [Abstract][Full Text] [Related]
29. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
[TBL] [Abstract][Full Text] [Related]
30. Opioid Overdose Deaths with Buprenorphine Detected in Postmortem Toxicology: a Retrospective Analysis.
Wightman RS; Perrone J; Scagos R; Krieger M; Nelson LS; Marshall BDL
J Med Toxicol; 2021 Jan; 17(1):10-15. PubMed ID: 32648229
[TBL] [Abstract][Full Text] [Related]
31. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.
Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ
Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843
[TBL] [Abstract][Full Text] [Related]
32. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.
Park TW; Saitz R; Ganoczy D; Ilgen MA; Bohnert AS
BMJ; 2015 Jun; 350():h2698. PubMed ID: 26063215
[TBL] [Abstract][Full Text] [Related]
33. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
34. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.
Abrahamsson T; Berge J; Öjehagen A; Håkansson A
Drug Alcohol Depend; 2017 May; 174():58-64. PubMed ID: 28315808
[TBL] [Abstract][Full Text] [Related]
35. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality.
Dasgupta N; Funk MJ; Proescholdbell S; Hirsch A; Ribisl KM; Marshall S
Pain Med; 2016 Jan; 17(1):85-98. PubMed ID: 26333030
[TBL] [Abstract][Full Text] [Related]
36. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Williams AR; Samples H; Crystal S; Olfson M
Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
[TBL] [Abstract][Full Text] [Related]
37. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
38. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.
Glanz JM; Binswanger IA; Clarke CL; Nguyen AP; Ford MA; Ray GT; Xu S; Hechter RC; Yarborough BJH; Roblin DW; Ahmedani B; Boscarino JA; Andrade SE; Rosa CL; Campbell CI
Addiction; 2023 Jan; 118(1):97-107. PubMed ID: 35815386
[TBL] [Abstract][Full Text] [Related]
39. Opioid prescribing history prior to heroin overdose among commercially insured adults.
Lagisetty P; Zhang K; Haffajee RL; Lin LA; Goldstick J; Brownlee R; Bohnert A; Larochelle MR
Drug Alcohol Depend; 2020 Jul; 212():108061. PubMed ID: 32428788
[TBL] [Abstract][Full Text] [Related]
40. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
Hughto JMW; Moyo P; Green TC
J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
